慢性リンパ性白血病治療薬の世界市場 2024-2028

慢性リンパ性白血病治療薬市場は2023-2028年に29億2,000万米ドル、予測期間中のCAGRは8.82％で成長すると予測されます。

当レポートでは、慢性リンパ性白血病治療薬市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、さまざまな血液がんに対する研究助成金の増加、慢性リンパ性白血病の有病率の増加、老年人口の増加によって牽引されています。

本調査では、慢性リンパ性白血病治療薬の特効薬指定が、今後数年間の慢性リンパ性白血病治療薬市場成長を牽引する主要な理由の一つであると特定しています。また、革新的な慢性リンパ性白血病治療薬に関する研究開発活動の増加や、慢性リンパ性白血病の診断のための予測バイオマーカーの使用の増加が、市場の大きな需要につながります。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模の評価

• 市場の定義
• 市場セグメント分析
• 市場規模 2023
• 市場の見通し 2023-2028

第4章 市場規模実績

• 慢性リンパ性白血病治療薬の世界市場 2018-2022
• 投与経路セグメント分析 2018-2022
• 治療セグメント分析 2018-2022
• 地域別セグメント分析 2018-2022
• 国別セグメント分析 2018-2022

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション：投与経路別

• 市場セグメント
• 比較：投与経路別
• 非経口：市場規模と予測 2023-2028
• 経口：市場規模と予測 2023-2028
• 市場機会：投与経路別

第7章 市場セグメンテーションセラピー

• 市場セグメント
• 比較セラピー
• 化学療法：市場規模と予測 2023-2028
• 標的療法：市場規模と予測 2023-2028
• その他：市場規模と予測 2023-2028
• 市場機会セラピー

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米：市場規模と予測 2023-2028
• 欧州：市場規模と予測 2023-2028
• アジア：市場規模と予測 2023-2028
• 世界のその他の地域：市場規模と予測 2023-2028
• 米国：市場規模と予測 2023-2028
• ドイツ：市場規模と予測 2023-2028
• 中国：市場規模と予測 2023-2028
• 日本：市場規模と予測 2023-2028
• 英国：市場規模と予測 2023-2028
• 市場機会：地域別

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Biogen Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Novartis AG
• Pfizer Inc.
• R2T BIOPHARMA INC
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market by Geography
• Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration
• Exhibits6: Executive Summary - Chart on Market Segmentation by Therapy
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits18: Historic Market Size - Data Table on global chronic lymphocytic leukemia therapeutics market 2018 - 2022 ($ billion)
• Exhibits19: Historic Market Size - Route Of Administration Segment 2018 - 2022 ($ billion)
• Exhibits20: Historic Market Size - Therapy Segment 2018 - 2022 ($ billion)
• Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
• Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
• Exhibits23: Five forces analysis - Comparison between 2023 and 2028
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
• Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
• Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
• Exhibits29: Chart on Market condition - Five forces 2023 and 2028
• Exhibits30: Chart on Route of Administration - Market share 2023-2028 (%)
• Exhibits31: Data Table on Route of Administration - Market share 2023-2028 (%)
• Exhibits32: Chart on Comparison by Route of Administration
• Exhibits33: Data Table on Comparison by Route of Administration
• Exhibits34: Chart on Parenteral - Market size and forecast 2023-2028 ($ billion)
• Exhibits35: Data Table on Parenteral - Market size and forecast 2023-2028 ($ billion)
• Exhibits36: Chart on Parenteral - Year-over-year growth 2023-2028 (%)
• Exhibits37: Data Table on Parenteral - Year-over-year growth 2023-2028 (%)
• Exhibits38: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
• Exhibits39: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
• Exhibits40: Chart on Oral - Year-over-year growth 2023-2028 (%)
• Exhibits41: Data Table on Oral - Year-over-year growth 2023-2028 (%)
• Exhibits42: Market opportunity by Route of Administration ($ billion)
• Exhibits43: Data Table on Market opportunity by Route of Administration ($ billion)
• Exhibits44: Chart on Therapy - Market share 2023-2028 (%)
• Exhibits45: Data Table on Therapy - Market share 2023-2028 (%)
• Exhibits46: Chart on Comparison by Therapy
• Exhibits47: Data Table on Comparison by Therapy
• Exhibits48: Chart on Chemotherapy - Market size and forecast 2023-2028 ($ billion)
• Exhibits49: Data Table on Chemotherapy - Market size and forecast 2023-2028 ($ billion)
• Exhibits50: Chart on Chemotherapy - Year-over-year growth 2023-2028 (%)
• Exhibits51: Data Table on Chemotherapy - Year-over-year growth 2023-2028 (%)
• Exhibits52: Chart on Targeted - Market size and forecast 2023-2028 ($ billion)
• Exhibits53: Data Table on Targeted - Market size and forecast 2023-2028 ($ billion)
• Exhibits54: Chart on Targeted - Year-over-year growth 2023-2028 (%)
• Exhibits55: Data Table on Targeted - Year-over-year growth 2023-2028 (%)
• Exhibits56: Chart on Others - Market size and forecast 2023-2028 ($ billion)
• Exhibits57: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
• Exhibits58: Chart on Others - Year-over-year growth 2023-2028 (%)
• Exhibits59: Data Table on Others - Year-over-year growth 2023-2028 (%)
• Exhibits60: Market opportunity by Therapy ($ billion)
• Exhibits61: Data Table on Market opportunity by Therapy ($ billion)
• Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits63: Chart on Market share by geography 2023-2028 (%)
• Exhibits64: Data Table on Market share by geography 2023-2028 (%)
• Exhibits65: Chart on Geographic comparison
• Exhibits66: Data Table on Geographic comparison
• Exhibits67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibits68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibits69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibits70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• Exhibits71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibits72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibits73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits75: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibits76: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibits77: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits83: Chart on US - Market size and forecast 2023-2028 ($ billion)
• Exhibits84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
• Exhibits85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibits86: Data Table on US - Year-over-year growth 2023-2028 (%)
• Exhibits87: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibits88: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibits89: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits91: Chart on China - Market size and forecast 2023-2028 ($ billion)
• Exhibits92: Data Table on China - Market size and forecast 2023-2028 ($ billion)
• Exhibits93: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibits94: Data Table on China - Year-over-year growth 2023-2028 (%)
• Exhibits95: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
• Exhibits96: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
• Exhibits97: Chart on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits98: Data Table on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibits100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibits101: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibits102: Data Table on UK - Year-over-year growth 2023-2028 (%)
• Exhibits103: Market opportunity by geography ($ billion)
• Exhibits104: Data Tables on Market opportunity by geography ($ billion)
• Exhibits105: Impact of drivers and challenges in 2023 and 2028
• Exhibits106: Overview on Criticality of inputs and Factors of differentiation
• Exhibits107: Overview on factors of disruption
• Exhibits108: Impact of key risks on business
• Exhibits109: Vendors covered
• Exhibits110: Matrix on vendor position and classification
• Exhibits111: AbbVie Inc. - Overview
• Exhibits112: AbbVie Inc. - Product / Service
• Exhibits113: AbbVie Inc. - Key news
• Exhibits114: AbbVie Inc. - Key offerings
• Exhibits115: Amgen Inc. - Overview
• Exhibits116: Amgen Inc. - Product / Service
• Exhibits117: Amgen Inc. - Key offerings
• Exhibits118: AstraZeneca PLC - Overview
• Exhibits119: AstraZeneca PLC - Product / Service
• Exhibits120: AstraZeneca PLC - Key news
• Exhibits121: AstraZeneca PLC - Key offerings
• Exhibits122: Biogen Inc. - Overview
• Exhibits123: Biogen Inc. - Product / Service
• Exhibits124: Biogen Inc. - Key news
• Exhibits125: Biogen Inc. - Key offerings
• Exhibits126: Bristol-Myers Squibb Company - Overview
• Exhibits127: Bristol-Myers Squibb Company - Product / Service
• Exhibits128: Bristol-Myers Squibb Company - Key news
• Exhibits129: Bristol-Myers Squibb Company - Key offerings
• Exhibits130: F. Hoffmann La Roche Ltd. - Overview
• Exhibits131: F. Hoffmann La Roche Ltd. - Business segments
• Exhibits132: F. Hoffmann La Roche Ltd. - Key news
• Exhibits133: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibits134: F. Hoffmann La Roche Ltd. - Segment focus
• Exhibits135: Gilead Sciences Inc. - Overview
• Exhibits136: Gilead Sciences Inc. - Product / Service
• Exhibits137: Gilead Sciences Inc. - Key news
• Exhibits138: Gilead Sciences Inc. - Key offerings
• Exhibits139: GlaxoSmithKline Plc - Overview
• Exhibits140: GlaxoSmithKline Plc - Business segments
• Exhibits141: GlaxoSmithKline Plc - Key news
• Exhibits142: GlaxoSmithKline Plc - Key offerings
• Exhibits143: GlaxoSmithKline Plc - Segment focus
• Exhibits144: Novartis AG - Overview
• Exhibits145: Novartis AG - Business segments
• Exhibits146: Novartis AG - Key news
• Exhibits147: Novartis AG - Key offerings
• Exhibits148: Novartis AG - Segment focus
• Exhibits149: Pfizer Inc. - Overview
• Exhibits150: Pfizer Inc. - Product / Service
• Exhibits151: Pfizer Inc. - Key news
• Exhibits152: Pfizer Inc. - Key offerings
• Exhibits153: R2T BIOPHARMA INC - Overview
• Exhibits154: R2T BIOPHARMA INC - Product / Service
• Exhibits155: R2T BIOPHARMA INC - Key offerings
• Exhibits156: Sanofi SA - Overview
• Exhibits157: Sanofi SA - Business segments
• Exhibits158: Sanofi SA - Key news
• Exhibits159: Sanofi SA - Key offerings
• Exhibits160: Sanofi SA - Segment focus
• Exhibits161: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibits162: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibits163: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibits164: Takeda Pharmaceutical Co. Ltd. - Key offerings
• Exhibits165: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibits166: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibits167: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibits168: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibits169: Teva Pharmaceutical Industries Ltd. - Segment focus
• Exhibits170: Inclusions checklist
• Exhibits171: Exclusions checklist
• Exhibits172: Currency conversion rates for US$
• Exhibits173: Research methodology
• Exhibits174: Validation techniques employed for market sizing
• Exhibits175: Information sources
• Exhibits176: List of abbreviations

The chronic lymphocytic leukemia therapeutics market is forecasted to grow by USD 2.92 bn during 2023-2028, accelerating at a CAGR of 8.82% during the forecast period. The report on the chronic lymphocytic leukemia therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing research grants for different blood cancers, the increasing prevalence of chronic lymphocytic leukemia, and the growing geriatric population.

Technavio's chronic lymphocytic leukemia therapeutics market is segmented as below:

By Route Of Administration

• Parenteral
• Oral

By Therapy

• Chemotherapy
• Targeted
• Others

By Geography

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the special drug designations for chronic lymphocytic leukemia therapeutics as one of the prime reasons driving the chronic lymphocytic leukemia therapeutics market growth during the next few years. Also, the rise in R&D activities related to innovative chronic lymphocytic leukemia therapeutics and increased use of predictive biomarkers for diagnosing chronic lymphocytic leukemia will lead to sizable demand in the market.

The report on the chronic lymphocytic leukemia therapeutics market covers the following areas:

• Chronic lymphocytic leukemia therapeutics market sizing
• Chronic lymphocytic leukemia therapeutics market forecast
• Chronic lymphocytic leukemia therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic lymphocytic leukemia therapeutics market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., R2T BIOPHARMA INC, Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the chronic lymphocytic leukemia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition
• 3.2 Market segment analysis
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

• 4.1 Global chronic lymphocytic leukemia therapeutics market 2018 - 2022
• 4.2 Route Of Administration Segment Analysis 2018 - 2022
• 4.3 Therapy Segment Analysis 2018 - 2022
• 4.4 Geography Segment Analysis 2018 - 2022
• 4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

• 5.1 Five forces summary
• 5.2 Bargaining power of buyers
• 5.3 Bargaining power of suppliers
• 5.4 Threat of new entrants
• 5.5 Threat of substitutes
• 5.6 Threat of rivalry
• 5.7 Market condition

6 Market Segmentation by Route of Administration

• 6.1 Market segments
• 6.2 Comparison by Route of Administration
• 6.3 Parenteral - Market size and forecast 2023-2028
• 6.4 Oral - Market size and forecast 2023-2028
• 6.5 Market opportunity by Route of Administration

7 Market Segmentation by Therapy

• 7.1 Market segments
• 7.2 Comparison by Therapy
• 7.3 Chemotherapy - Market size and forecast 2023-2028
• 7.4 Targeted - Market size and forecast 2023-2028
• 7.5 Others - Market size and forecast 2023-2028
• 7.6 Market opportunity by Therapy

8 Customer Landscape

• 8.1 Customer landscape overview

9 Geographic Landscape

• 9.1 Geographic segmentation
• 9.2 Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• 9.4 Europe - Market size and forecast 2023-2028
• 9.5 Asia - Market size and forecast 2023-2028
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• 9.7 US - Market size and forecast 2023-2028
• 9.8 Germany - Market size and forecast 2023-2028
• 9.9 China - Market size and forecast 2023-2028
• 9.10 Japan - Market size and forecast 2023-2028
• 9.11 UK - Market size and forecast 2023-2028
• 9.12 Market opportunity by geography

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• 11.3 Landscape disruption
• 11.4 Industry risks

12 Vendor Analysis

• 12.1 Vendors covered
• 12.2 Market positioning of vendors
• 12.3 AbbVie Inc.
• 12.4 Amgen Inc.
• 12.5 AstraZeneca PLC
• 12.6 Biogen Inc.
• 12.7 Bristol-Myers Squibb Company
• 12.8 F. Hoffmann La Roche Ltd.
• 12.9 Gilead Sciences Inc.
• 12.10 GlaxoSmithKline Plc
• 12.11 Novartis AG
• 12.12 Pfizer Inc.
• 12.13 R2T BIOPHARMA INC
• 12.14 Sanofi SA
• 12.15 Takeda Pharmaceutical Co. Ltd.
• 12.16 Teva Pharmaceutical Industries Ltd.

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• 13.3 Currency conversion rates for US$
• 13.4 Research methodology
• 13.5 List of abbreviations